OCEAN

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)

 

 

 

PATIENTS

Recruitment was stopped on the 27th of May 2022.
 

1240 patients enrolled (136 in Germany)
55 sites open (10 in Germany)


Status as of 06th of May 2022


1.572

(375 in Germany)

Planned number of participants

 

PARTICIPATING COUNTRIES

Australia, Belgium, China, Germany, Israel, Italy, Canada

 

Chief International Investigators

Dr. David H. Birnie, Ottawa Heart Institute Research Corporation, Canada
Dr. Atul Verma, Southlake Regional Health Center, Ontario, Canada
Dr. Gerhard Hindricks, Leipzig Heart Centre, Germany

 

Overall Responsibility 

Sponsor:

Ottawa Heart Institute Research Corporation (OHIRC), Canada

Legal Sponsor Representative for Europe:

Atrial Fibrillation NETwork (AFNET), Münster, Germany

 

Registration

ClinicalTrials.gov: NCT02168829

EudraCT: 2016-002353-38